Drugs / PMCC-COE-KMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07541391 | May 2026 → Sep 2028 expected | refractory plasma cell neoplasm | Peter MacCallum Cancer Centre, Australia | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PMCC-COE-KMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07541391 ↗ |
| Action | Deplete | “triggering target cell destruction” NCT07541391 ↗ |
| Modality | Cell therapy | “cellular immunotherapy” NCT07541391 ↗ |